Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with prostate cancer
Prostate Cancer
DRUG: Leuprolide Acetate|DRUG: Leuprolide Acetate
Peak Plasma Concentration (Cmax), Day 99|Area under the plasma concentration versus time curve (AUC), AUC0-7, AUC7-28, AUC 0-42, AUCt, AUCinf, Day 99
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with prostate cancer